Drug Profile
Lactoferrin - Metrodora Therapeutics
Alternative Names: Bovine lactoferrin - Metrodora TherapeuticsLatest Information Update: 11 Apr 2022
Price :
$50
*
At a glance
- Originator Metrodora Therapeutics
- Class Adjuvants; Anti-inflammatories; Antibacterials; Antifungals; Glycoproteins; Iron binding proteins; Proteins
- Mechanism of Action Chelating agents; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bacterial vaginosis
- No development reported Crohn's disease
Most Recent Events
- 07 Apr 2022 Metrodora Therapeutics plans a phase I trial for Bacterial vaginosis (Prevention) in Australia (Vaginal) in April 2022 (ACTRN12622000548730)
- 08 Nov 2021 Phase-I clinical trials in Bacterial vaginosis (In volunteers) (Vaginal) in Australia (ACTRN12621000862842)
- 05 Jul 2021 Metrodora Therapeutics plans a phase I trial for Bacterial Vaginosis (In volunteers) in Australia (Vaginal), in August 2021 (ACTRN12621000862842p)